H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Timber Pharmaceuticals (TMBR – Research Report) today and set a price target of $1.50. The company's shares closed last Friday at $0.25, close to its 52-week low of $0.24. According to TipRanks.com, Selvaraju is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -41.5% and a 10.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, Oncternal Therapeutics, and Inovio Pharmaceuticals. Currently, the analyst consensus on Timber Pharmaceuticals is a Moderate Buy with an average price target of $1.50.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-timber-pharmaceuticals-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Timber Pharmaceuticals (AMEX:TMBR)
Historical Stock Chart
From Jun 2022 to Jul 2022 Click Here for more Timber Pharmaceuticals Charts.
Timber Pharmaceuticals (AMEX:TMBR)
Historical Stock Chart
From Jul 2021 to Jul 2022 Click Here for more Timber Pharmaceuticals Charts.